title: Therapeutic and cosmetic applications of Evodiamine and its derivatives--A patent review.
abstract: Evodiamine, ((+)-(S)-8,13,13b,14-tetrahydro-14-methylindolo[2',3':3,4]pyrido[2,1-b]quinazolin-5(7H)-one) indoloquinazoline alkaloid, is the major component isolated from the fruits of Evodia rutaecarpa, family Rutaceae. Broad spectrum of pharmacological activities of Evodiamine suggests its imperative role in treating a variety of diseases influencing the function of diverse targets. A comprehensive search was carried out to collect patent information regarding Evodiamine and its derivatives using different patent databases covering priority years to till date. The patents claiming therapeutic as well as cosmetic applications of Evodiamine and its derivatives were analyzed in detail and were classified technically based on the its application such as treatment of metabolic disorders, cancer, neurological disorders, and cardiovascular disorders, etc. The analysis revealed that the use and the mode of actions of Evodiamine and its derivatives in weight management treatments are currently well established. For example the fat reducing property of this alkaloid is primarily due to its mode of actions such as prevention of muscle protein catabolism, enhancement of thermogenesis and lipid oxidation. Apart from its use for treating obesity, Evodiamine and its derivatives are also experimentally explored for their anti-cancer, anti-diabetic and anti-inflammatory properties. The possible mechanisms related to its anti-cancer activity as illustrated by different experimental studies include its potential action as modulator of specific receptors such as topoisomerase I, NF-kappa B and B-cell lymphoma 2 (Bcl2). The analysis hence highlights that, clinical studies pertaining to the anti-cancer, anti-diabetes as well as anti-inflammatory activities of the Evodiamine and its derivatives would possess important market potential for the development of Evodiamine based therapeutics.
authors.affiliation: CSIR Unit for Research and Development of Information Products. "Tapovan", NCL Campus, S. No. 113, 114, Pashan, Pune 411 008, India. Electronic address: kirti.deshmukh510@gmail.com.
authors.forename: Kirti
authors.initials: K
authors.lastname: Gavaraskar
authors.affiliation: CSIR Unit for Research and Development of Information Products. "Tapovan", NCL Campus, S. No. 113, 114, Pashan, Pune 411 008, India. Electronic address: sivakami@urdip.res.in.
authors.forename: Sivakami
authors.initials: S
authors.lastname: Dhulap
authors.affiliation: CSIR Unit for Research and Development of Information Products. "Tapovan", NCL Campus, S. No. 113, 114, Pashan, Pune 411 008, India. Electronic address: hirwani@urdip.res.in.
authors.forename: R R
authors.initials: RR
authors.lastname: Hirwani
mesh_terms: D000470:Alkaloids / Q000494:pharmacology*; D000818:Animals; D001327:Autoimmune Diseases / Q000188:drug therapy; D045744:Cell Line, Tumor; D002493:Central Nervous System Diseases / Q000188:drug therapy; D003358:Cosmetics / Q000737:chemistry; D032086:Evodia / Q000737:chemistry; D005638:Fruit / Q000737:chemistry; D006801:Humans; D007249:Inflammation / Q000188:drug therapy; D008659:Metabolic Diseases / Q000188:drug therapy; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy; D010330:Patents as Topic; D011799:Quinazolines / Q000494:pharmacology*
chemical_list: D000470:Alkaloids; D003358:Cosmetics; D011799:Quinazolines; C049639:evodiamine
keywords: Bioactive; Cancer; Diabetes; Evodia rutaecarpa; Evodiamine; Inflammation; Medicinal plants; Obesity; Patent analysis